Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose methylprednisolone for severe COVID-19 pneumonia
IRCT20200611047727N3Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylprednisolone in coronavirus disease 2019 (COVID-19) and pneumonia (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Radiological changes. Started Jul 2020; status: completed.
02
Drugs
methylprednisolone
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on IRCT20200611047727N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200611047727N3.